We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Dedicated Blood DNA Collection Tube Receives European Marketing Approval

By LabMedica International staff writers
Posted on 13 Feb 2014

Image: The PAXgene Blood DNA Tube (Photo courtesy of PreAnalytiX GmbH).

Image: The PAXgene Blood DNA Tube (Photo courtesy of PreAnalytiX GmbH).

A new collection tube for routine clinical use that was designed to preserve DNA in blood samples was recently certified for use as a diagnostic product in Europe.

The PreAnalytiX GmbH (Feldbachstrasse, Switzerland) PAXgene Blood DNA Tube provides a means for the collection of whole blood for the isolation of genomic DNA in a closed, evacuated system. Blood is collected under a standard phlebotomy protocol into an evacuated tube that contains potassium-EDTA additive. Complete isolation of DNA is carried out using manual or automated methods such as salting out precipitation, magnetic beads, or silica membrane-based technologies.

The 2.5 milliliter PAXgene Blood DNA Tube stabilizes genomic DNA with validated time and temperature parameters. The tube incorporates workflow efficiency features including a two-dimensional bar code on the label and a tube closure that clearly identifies this unique DNA collection tube.

The PAXgene tube, which recently received the European Union's CE marking IVD certification for sale in Europe was developed as part of a joint venture between Becton Dickinson and Company ((Franklin Lakes, NJ, USA) and QIAGEN (Venlo, The Netherlands).

“The validated performance data we provide to clinical scientists for the PAXgene Blood DNA Tube should reduce the chances of preanalytical error, ensuring the best quality sample for accurate IVD test performance and for blood DNA storage related to the identification of new biomarkers of disease or drug actions,” said Frank Augello, general manager of PreAnalytiX GmbH.

Related Links:
PreAnalytiX GmbH
Becton Dickinson and Company
QIAGEN

Visit expo >

Gold Member

Neonatal Heel Incision Device

Tenderfoot

Online QC Software
Acusera 24•7

HPV Molecular Test

BD Onclarity HPV Assay

LAIR2 Antibody Pair Set

LAIR2 Antibody Pair [Biotin]

Latest Technology News

Channels

Molecular Diagnostics

view channel

Point-of-Care Molecular Technology Promises Transformative Shift in Oncology

Delays in obtaining molecular test results can hinder timely oncology decisions and widen disparities for patients far from centralized laboratories. Prolonged waits may also heighten anxiety and increase... Read more

New Test Delivers Four Prenatal Genetic Screens from One Blood Sample

Prenatal genetic screening often requires multiple tests, blood draws, and follow-up appointments, delaying access to clinically relevant information. Early, consolidated insights may help clinicians coordinate... Read more

Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions

Vesicular and pustular skin lesions can stem from multiple viral pathogens, complicating timely diagnosis and management. Sequential single-pathogen testing can miss infections when the causative agent... Read more

Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer

Radium-223 dichloride is a bone-targeted radiopharmaceutical therapy that improves overall survival and quality of life for many patients with metastatic castration-resistant prostate cancer (mCRPC), but... Read more

Hematology

view channel

Image: Despite treatment advances, most multiple myeloma patients relapse and identifying high-risk cases at diagnosis remains challenging (Image Credit: Adobe Stock)

New Marker Helps Detect Aggressive Multiple Myeloma Earlier

Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read more

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

AI Decision Support System Guides Treatment Selection for Complex Blood Cancers

Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read more

Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack

ST-elevation myocardial infarction (STEMI) is a severe heart attack caused by complete blockage of a coronary artery. Early risk stratification at hospital admission is challenging but essential for guiding... Read more

Immunology

view channel

Image: A new study shows that an ultrasensitive blood test can detect immune signaling patterns associated with Sjögren’s disease more than a decade before diagnosis (Image Credit: 123RF)

Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis

Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more

New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients

Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read more

Cell-Free Assay Detects Functional IgE for Food Allergy Diagnosis

Accurately distinguishing sensitization from clinically relevant food allergy remains a challenge for laboratories, as routine blood tests detect allergen-specific immunoglobulin E (IgE) but not its capacity... Read more

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Microbiology

view channel

Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation

U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more

Image: The addition builds on a QIAstat-Dx menu that also includes respiratory, gastrointestinal, and meningitis/encephalitis panels (Photo courtesy of Qiagen)

Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections

Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read more

Image: Graphical Abstract (Ahavi P, Hoang TN, Meyer P, et al. Cell Systems, 2026; doi:10.1016/j.cels.2026.101654)

Bacterial Growth Assay Predicts COVID-19 Severity From Plasma

COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read more

Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults

Frailty in older adults is marked by increased vulnerability to disease, falls, functional decline, and death, yet its biological drivers remain incompletely understood. Because the gut microbiota influences... Read more

Pathology

view channel

Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response

Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read more

Image: Atypical clustering of myeloid progenitor cells called myeloblasts (white arrows), defined by their co-expression of CD34 (magenta) and CD117 (green), in a bone marrow biopsy tissue from a patient with MDS. (Image Credit: Dr. Sanjay Patel)

AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity

Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read more

Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue

Mapping the spatial distribution of disease-relevant molecules within tissue remains a diagnostic challenge, particularly before alterations are visible by conventional microscopy. In Fabry disease, a... Read more

Image credit: Adobe Stock

AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer

Lung cancer is the leading cause of cancer-related death, and many patients require rapid genotyping to guide targeted therapy selection. Current workflows often rely on molecular tests that are costly,... Read more

Technology

view channel

Training Device Improves Accuracy of Pooled Molecular Diagnostics

High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more

New CE-Certified Software Advances Whole-Genome Cancer Testing

European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more

National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care

Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more

AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines

Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more

Industry

view channel

Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal

Tempus AI, Inc. (Chicago, IL, USA) has entered into a definitive agreement to acquire Personalis, Inc. (Fremont, CA, USA), expanding its capabilities in molecular residual disease (MRD) testing and cancer... Read more

Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections

Bruker Corporation has acquired the DISQVER clinical metagenomics platform from Noscendo GmbH, expanding its next-generation sequencing infection detection portfolio. Following the acquisition, DISQVER... Read more

Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition

Leica Biosystems, an operating company of Danaher, has entered into a definitive agreement to acquire privately held StatLab Medical Products from Linden Capital Partners and Audax Private Equity.... Read more

Seed Amplification Test Expands Access to Neurodegenerative Disease Testing

Amprion, Inc. has secured a multi-million-dollar growth investment from Decathlon Capital Partners to expand its diagnostic testing capacity for neurodegenerative diseases. The San Diego-based company... Read more